Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study
Ann Oncol. 2015 Jul;26(7):1518.
doi: 10.1093/annonc/mdv241.
1 INSERM Unit U981, Institut Gustave Roussy, Villejuif, France Department of Oncological and Surgical Sciences, University of Padua, Padua Division of Medical Oncology 2, Istituto Oncologico Veneto IRCCS, Padova.
2 Early Drug Development for Innovative Therapies Division, Department of Medicine, Istituto Europeo di Oncologia, Milano.
3 INSERM Unit U981, Institut Gustave Roussy, Villejuif, France.
4 Department of Pathology, Istituto Europeo di Oncologia, Milano Faculty of Medicine, University of Milan, Milano.
5 Department of Oncological and Surgical Sciences, University of Padua, Padua Division of Medical Oncology 2, Istituto Oncologico Veneto IRCCS, Padova.
6 Division of Pathology, Modena University Hospital, Modena, Italy.
7 Departments of Medical Biology and Pathology.
8 INSERM Unit U981, Institut Gustave Roussy, Villejuif, France Medical Oncology, Institut Gustave Roussy, Villejuif.
9 INSERM Unit U981, Institut Gustave Roussy, Villejuif, France Medical Oncology, Institut Gustave Roussy, Villejuif Faculty of Medicine, Paris Sud University, Kremlin-Bicêtre, France.